PULSE BIOSCIENCES, INC. (PLSE) Form 8-K — Aug 6, 2026
Pulse Biosciences reported second quarter 2026 results on August 6, 2026, posting total revenue of $0.4 million ($434 thousand, up sequentially) against a GAAP net loss of $24.7 million, wider than the $19.2 million loss a year earlier. Non-GAAP net loss was $19.4 million versus $13.7 million in the prior-year quarter, on GAAP costs and expenses of $25.7 million. Clinical momentum was the headline: the NANOPULSE-AF U.S.
Key figures
- Eps
- -$0.36 (basic and diluted) vs. -$0.28 prior year
- Revenue
- $434,000 (Q2 2026 product revenue; up sequentially from Q1)
- Net Income
- -$24.7 million GAAP net loss vs. -$19.2 million prior-year quarter
- Total Assets
- $115.6 million
- Cash Position
- $101.6 million as of June 30, 2026 (vs. $68.3 million at March 31, 2026 and $106.3 million at June 30, 2025)
- Shares Outstanding
- 70799962
- New ATMFacility
- $75 million
- Non GAAPNet Loss
- -$19.4 million vs. -$13.7 million prior-year quarter
- ATMNet Proceeds Q2
- $46.8 million (approx. $13 million from insiders, $33.8 million from outside investors)
- Operating Cash Use
- $18.7 million in Q2 2026 vs. $12.8 million prior-year quarter
- Post Quarter Raises
- $10.7 million net ATM proceeds plus $1.8 million gross from warrant exercises
- Shelf Registration
- up to an additional $125 million
- GAAPCosts And Expenses
- $25.7 million, up $5.4 million YoY from $20.3 million
- NANOPULSEAFEnrollment
- >82 evaluable patients; target increased by 19 patients to 164
- Non GAAPCosts And Expenses
- $20.5 million, up $5.7 million YoY from $14.8 million
- Active Investigational Sites
- 12
Price after filing
1 day: -0.7%7 days: +17.7%30 days: +39.5%
Close on the filing date to close N calendar days later (from $38.17). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.